Updated:
The Progeria Research Foundation
The Progeria Research Foundation is a nonprofit founded in 1999 by Dr.
The Progeria Research Foundation
The Progeria Research Foundation (PRF) was founded in 1999 by Dr. Leslie Gordon and her husband Dr. Scott Berns, following their son Sam's diagnosis with Hutchinson-Gilford progeria syndrome (HGPS). The family-driven effort has become the primary catalyst for progeria research globally, leveraging a focused mandate that differs from typical multi-disease foundations. Wealth origin is not applicable in the traditional sense — PRF is a nonprofit, not a wealth management entity. PRF's strategy centers on funding research grants, clinical trials, and scientific conferences. Key investments include the Progeria Clinical Trials program, which began enrolling patients in 2007 and tested lonafarnib, a farnesyltransferase inhibitor that later received FDA approval in 2020. The foundation also supports basic science at institutions such as Boston Children's Hospital and the National Institutes of Health. Geographic reach is primarily United States-based, with collaborations extending to Europe and Australia. The organization has awarded over $30 million in research funding since inception, with a small paid staff and reliance on donations. A significant operational event was the FDA approval of lonafarnib (Zokinvy) in November 2020, marking the first treatment specifically for progeria (per FDA announcement, 2020). PRF also maintains the Progeria Registry and a cell/tissue bank to accelerate research. PRF's structural differentiator is its single-disease focus combined with a family-founded governance model — rare among medical foundations. Unlike broad-based research charities, PRF controls a tightly integrated program from basic research through clinical trials to FDA approval, functioning almost as a vertically integrated drug development entity within the nonprofit space.
General information
Firm type
Foundation
Year founded
1999
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Peabody
Corporate office
Peabody, MA, United States
Principals
Dr. Leslie Gordon
Medical Director
Scott Berns
Chief Executive Officer
Sector focus
Frequently asked questions
Who runs investment decisions at The Progeria Research Foundation?
The foundation's scientific and medical direction is led by Dr. Leslie Gordon, medical director, and CEO Scott Berns. Research funding decisions are guided by a medical research committee and external peer review, not individual investment professionals. PRF's board of directors oversees strategic priorities and budget allocation.
How does The Progeria Research Foundation source research proposals?
PRF issues open Requests for Proposals (RFPs) targeting progeria and related laminopathy research. The foundation also proactively identifies promising researchers through its annual scientific conferences and maintains a grant portfolio that spans basic science to translational projects. Priority is given to proposals that accelerate clinical applications.
Is The Progeria Research Foundation a family office or a charitable foundation?
It is a 501(c)(3) nonprofit charitable foundation, not a family office. PRF does not manage private wealth or allocate capital for families. Its revenue comes entirely from donations, grants, and fundraising events. Any references to 'family office' are incorrect in this context.
What treatment milestone has The Progeria Research Foundation achieved?
In 2020, the FDA approved Zokinvy (lonafarnib) as the first-ever treatment for progeria, based on clinical trials funded by PRF. The drug extends survival and improves cardiovascular outcomes. This approval represents a significant return on the foundation's research investment.
Does The Progeria Research Foundation invest in for-profit biotech companies?
PRF primarily awards grants to academic institutions and nonprofit research organizations. It does not typically make equity investments in for-profit biotech companies. The foundation's model relies on direct research funding rather than venture capital-style deployment.
What geographic regions does The Progeria Research Foundation support?
The foundation's research funding is global, though most awarded grants go to U.S. institutions. PRF maintains collaborative relationships with researchers in Canada, Europe, Australia, and Japan. The Progeria Registry includes patients from over 40 countries, enabling worldwide data collection and clinical trial access.
How is The Progeria Research Foundation structured differently from other disease-focused foundations?
PRF is uniquely vertically integrated for a rare-disease organization: it funds research, runs a clinical trials network, maintains a patient registry and cell bank, and advocates for regulatory approval. This end-to-end approach — from bench science to drug approval — is rare among foundations of its size and scope.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: